Differential action of methamphetamine on tyrosine hydroxylase and dopamine transport in the nigrostriatal pathway of μ-opioid receptor knockout mice

International Journal of Neuroscience

Volumn 122, Issue 6, 2012, Pages 305-313

  Park, Sang Won ^a   He, Zhi ^a   Shen, Xine ^b   Roman, Richard J ^a   Ma, Tangeng ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

opioid receptor knockout mice; Dopamine transporter; Methamphetamine; Tyrosine hydroxylase

Indexed keywords

DOPAMINE TRANSPORTER; MESSENGER RNA; METHAMPHETAMINE; MU OPIATE RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KNOCKOUT MOUSE; MOUSE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ANIMALS; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; IODINE RADIOISOTOPES; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURAL PATHWAYS; NEURONS; RADIOPHARMACEUTICALS; RECEPTORS, OPIOID, MU; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84861073650     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.652319     Document Type: Article

References (49)

1. Volz TJ, Fleckenstein AE, Hanson GR. Methamphetamineinduced alterations in monoamine transport: Implications for neurotoxicity, neuroprotection and treatment. Addiction. 2007;102(Suppl 1):44-8.
2. Berman S, O'Neill J, Fears S, Bartzokis G, London ED. Abuse of amphetamines and structural abnormalities in the brain. Ann NY Acad Sci. 2008;1141:195-220.
3. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol. 1992;320: 145-60.
4. Trujillo KA, Belluzzi JD, Stein L. Naloxone blockade of amphetamine place preference conditioning. Psychopharmacology (Berlin). 1991;104:265-74.
5. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by conditioned place preference paradigm in rats. J Pharmacol Exp Ther. 1993;264:489-95.
6. Suzuki T, Mori T, Tsuji M, Misawa M, Nagase H. The role of the delta-opioid receptor subtypes in cocaine and methamphetamine-induced place preferences. Life Sci. 1994;55:L339-44.
7. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, Yamamura HI. Molecular biology and pharmacology of cloned opioid receptors. The FASEB J. 1995;9:516-25.
8. Wang JQ, McGinty JF. Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain. J Neurochem. 1995;65:2706-15.
9. Hodler C, Paquet B, Gilbert F, Drolet G, Levesque D, Rouillard C. Role of endogenous enkephalin and dynorphin in amphetamine induced behavioral sensitization [abstract]. Proceedings of the 35th Annual Meeting of the Society of Neuroscience; 2005 Nov 12-16; Washington, DC, p. 1029.7.
10. Feigenbaum JJ, Howard SG. Effects of naloxone on amphetamine-induced striatal dopamine release in vivo: A microdialysis study. Life Sci. 1997;60:1659-68.
11. Schad CA, Justice JB Jr, Holtzman SG. Endogenous opioids in dopaminergic cell body regions modulates amphetamineinduced increases in extracellular dopamine levels in the terminal regions. J Pharmacol Exp Ther. 2002;300:932-8.
12. Chiu CT, Ma T, Ho IK. Attenuation of methamphetamineinduced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull. 2005;67:100-9.
13. Robinson TE, Berridge KC. The neural basis of drug craving; an incentive-sensitization theory of addiction. Brain Res Rev. 1993;18:247-91.
14. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction. 2000;95(Suppl 2):S91-117.
15. Itzhak Y, Martin JL, Ali SF. Methamphetamine-induced dopaminergic neurotoxicity in mice: long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine. Prog Neuropsychopharmacol Biol Psychiat. 2002;26:1177-83.
16. Steketee JD, Kalivas PW. Drug wanting: Behavioral sensitization and relapse to drug-seeking behavior. Pharmacol Rev. 2011;63:348-65.
17. CassWA. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Exp Ther. 1997;280:105-13.
18. Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ, Marshall JF. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 1992;598:321-6.
19. Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamineinduced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci. 1999;19:9141-8.
20. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2:699-703.
21. Gehrke BJ, Cass WA, Bardo MT. Monoamine-depleting doses of methamphetamine in enriched and isolated rats: Consequences for subsequent methamphetamine-induced hyperactivity and reward. Behav Pharmacol. 2006;17:499-508.
22. Lan KC, Ma T, Lin-Shiau SY, Liu SH, Ho IK. Methamphetamine-elicited alterations of dopamine- and serotonin-metabolite levels within mu-opioid receptor knockout mice: A microdialysis study. J Biomed Sci. 2008;15: 391-403.
23. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN. μ- Opioid receptor knockout in mice: Effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res. 1998;54:321-6.
24. Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC. Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse. 1995;21:364-72.
25. Tien LT, Ho IK, Loh HH, Ma T. Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice. J Neurosci Res. 2007;85:673-80.
26. Paxinos G, Franklin KBJ. The mouse brain in stereotoxic coordinates. 2nd ed. San Diego, CA: Academic Press; 2001.
27. Shen X, Purser C, Tien LT, Chiu CT, Paul IA, Baker R, Loh HH, Ho IK, Ma T. mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. J Neurosci Res. 2010;88(10):2294-302.
28. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci. 1998;95:4029-34.
29. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980;181:151-60.
30. Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL. Differential toxic effects of methamphetamine (METH) andmethylenedioxymethamphetamine (MDMA) inmultidrugresistant (mdr1a) knockout mice. Brain Res. 1997;769:340-6.
31. Guilarte TR, Nihei MK, McGlothan JL, Howard AS. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: Distal axotomy or neuronal plasticity. Neuroscience. 2003;122:499-513.
32. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol. 2001;11:449-55.
33. Wang H, Moriwaki A, Wang JB, Uhl GR, Pickel VM. Ultrasctructural immunosytochemical localization of mu-opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate-putamen nucleus. Neuroscience. 1997;81:757-71.
34. Sharif NA, Hughes J. Discrete mapping of brain mu and delta opioid receptors using selective peptides: Quantitative autoradiography, species differences and comparison with kappa receptors. Peptides. 1989;10:499-522.
35. Mansour A, Fox CA, Akil H, Watson SJ. Opioidpreceptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci. 1995;18:22-9.
36. Devine DP, Leone P, Pocock D, Wise RA. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J Pharmacol Exp Ther. 1993;266:1236-46.
37. Bjorklund A and Lindvall O. Dopamine-containing systems in the CNS. In A. Bjorklund and T. Hokfelt (Eds.), Handbook of Chemical Neuroanatomy. Vol. 2: Classical Transmitters in the CNS, Part I, Elsevier Science Publishers, Amsterdam, 1984, pp. 55-122.
38. Sonsalla PK, Jochnowits ND, Zeevalk GD, Oosteen JA, Hall ED. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 1996;738: 172-5.
39. Hirata H, Cadet JL. p53-Knockout mice are protected against the long-Term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem. 1997;69:780-90.
40. Pavón N, Martín AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPAinduced dyskinesia in hemiparkinsonian mice. Biol Psychiat. 2006;59:64-74.
41. Darmopil S, Muneton-Gomez VC, de Ceballos ML, Bernson M, Moratalla R. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Eur J Neurosci. 2008;27:580-92.
42. Darmopil S, Martín AB,Diego IR, Ares S,Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits LDOPA- induced dyskinesia and histone activation. Biol Psychiat. 2009;66:603-13.
43. Thomas DM, Francescutti-Verbeem DM, Kuhn DM. Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem. 2009;109:1745-55.
44. Seiden LS, Ricaurte GA. Neurotoxicity of methamphetamine and related drugs. In:MeltzerHY, editor. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987. 359-66
45. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine; effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639-77.
46. Kogan FJ, Nichols WK, Gibb JW. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol. 1976;36:363-71.
47. Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamineinduced dopaminergic deficits and refractoriness to subsequent treatment. Eur J Pharmacol. 2009;607(1-3):68-73.
48. Wang JQ, McGinty JF. D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse. 1996;22:114-22.
49. Smith MP, Cass WA. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience. 2007;144:1057-66.